新型冠状病毒(COVID-19)的miRNA-PEPTIDE融合疫苗

{"title":"新型冠状病毒(COVID-19)的miRNA-PEPTIDE融合疫苗","authors":"","doi":"10.47485/2693-2458/1010","DOIUrl":null,"url":null,"abstract":"A new coronavirus named COVID-19 was reported in Wuhan, China in December 2019. The COVID-19 epidemic is spreading rapidly all over the world, (Sun P. and col, 2020). Based on published data on COVID-19, we have designed a preventive vaccine in Silico aimed to protect against COVID-19 infection and transmission (Cascella M. and col, 2020). One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors (Wang Z., 2019). Here, we present to the miRNA-peptide fusion more stable as antiviral (Waterhouse A. and col 2018). As RNA target we used primers from Kemp V. “miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs”: primers Biolegio, Nijmegen, The Netherlands (Kemp V. and col, 2019). Our analysis identified a miRNA-peptide with theorical fusion value stability FS=64.28, to treat COVID-19, named LCR_2020_B008-1. Additionally, peptide LCR_2020_B008 can be used in solutions as disinfectant and antiviral, having a fast-hygienic utility to avoid contagion or the propagation of the Covid-19 disease. With respect to antiviral action, the candidate manifests LCR_2020_B008-1, in Silico, manifesting partial inhibiting activity on the VIH-1, and therefore readjustments on this chimera miRNA-peptide could reach a representative antiviral activity against the VIH-1.","PeriodicalId":424815,"journal":{"name":"Journal of Diabetes and Endocrinology Research","volume":"345 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"A miRNA-PEPTIDE FUSION AS A VACCINE CANDIDATEAGAINST THE NOVEL CORONAVIRUS (COVID-19)\",\"authors\":\"\",\"doi\":\"10.47485/2693-2458/1010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A new coronavirus named COVID-19 was reported in Wuhan, China in December 2019. The COVID-19 epidemic is spreading rapidly all over the world, (Sun P. and col, 2020). Based on published data on COVID-19, we have designed a preventive vaccine in Silico aimed to protect against COVID-19 infection and transmission (Cascella M. and col, 2020). One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors (Wang Z., 2019). Here, we present to the miRNA-peptide fusion more stable as antiviral (Waterhouse A. and col 2018). As RNA target we used primers from Kemp V. “miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs”: primers Biolegio, Nijmegen, The Netherlands (Kemp V. and col, 2019). Our analysis identified a miRNA-peptide with theorical fusion value stability FS=64.28, to treat COVID-19, named LCR_2020_B008-1. Additionally, peptide LCR_2020_B008 can be used in solutions as disinfectant and antiviral, having a fast-hygienic utility to avoid contagion or the propagation of the Covid-19 disease. With respect to antiviral action, the candidate manifests LCR_2020_B008-1, in Silico, manifesting partial inhibiting activity on the VIH-1, and therefore readjustments on this chimera miRNA-peptide could reach a representative antiviral activity against the VIH-1.\",\"PeriodicalId\":424815,\"journal\":{\"name\":\"Journal of Diabetes and Endocrinology Research\",\"volume\":\"345 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes and Endocrinology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47485/2693-2458/1010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Endocrinology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47485/2693-2458/1010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

2019年12月,中国武汉出现了新型冠状病毒COVID-19。新冠肺炎疫情正在全球迅速蔓延,(Sun P. and col, 2020)。根据已公布的COVID-19数据,我们在硅设计了一种预防性疫苗,旨在防止COVID-19感染和传播(Cascella M. and col, 2020)。这样做的一个目的是更好地了解潜在的休眠储存库和这些储存库的潜在传播,以及潜在的地质地形因素(Wang Z., 2019)。在这里,我们提出了更稳定的mirna -肽融合作为抗病毒药物(Waterhouse A. and col 2018)。作为RNA靶标,我们使用的引物来自Kemp V.“miRNA库和宿主免疫因子对禽冠状病毒感染鸡蛋的调控”:引物Biolegio, Nijmegen,荷兰(Kemp V. and col, 2019)。我们的分析确定了一个理论融合值稳定性FS=64.28的mirna肽,命名为LCR_2020_B008-1,用于治疗COVID-19。此外,肽LCR_2020_B008可作为消毒剂和抗病毒药物在溶液中使用,具有快速卫生效用,可避免Covid-19疾病的传染或传播。在抗病毒作用方面,该候选物在硅片上表现为LCR_2020_B008-1,对VIH-1具有部分抑制活性,因此对该嵌合体miRNA-peptide进行调整,可达到对VIH-1具有代表性的抗病毒活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A miRNA-PEPTIDE FUSION AS A VACCINE CANDIDATEAGAINST THE NOVEL CORONAVIRUS (COVID-19)
A new coronavirus named COVID-19 was reported in Wuhan, China in December 2019. The COVID-19 epidemic is spreading rapidly all over the world, (Sun P. and col, 2020). Based on published data on COVID-19, we have designed a preventive vaccine in Silico aimed to protect against COVID-19 infection and transmission (Cascella M. and col, 2020). One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors (Wang Z., 2019). Here, we present to the miRNA-peptide fusion more stable as antiviral (Waterhouse A. and col 2018). As RNA target we used primers from Kemp V. “miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs”: primers Biolegio, Nijmegen, The Netherlands (Kemp V. and col, 2019). Our analysis identified a miRNA-peptide with theorical fusion value stability FS=64.28, to treat COVID-19, named LCR_2020_B008-1. Additionally, peptide LCR_2020_B008 can be used in solutions as disinfectant and antiviral, having a fast-hygienic utility to avoid contagion or the propagation of the Covid-19 disease. With respect to antiviral action, the candidate manifests LCR_2020_B008-1, in Silico, manifesting partial inhibiting activity on the VIH-1, and therefore readjustments on this chimera miRNA-peptide could reach a representative antiviral activity against the VIH-1.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信